InspireMD Inc. NSPR 深 沪
已收盘 02-06 16:00:00 美东时间
1.74
+0.100
+6.10%
华盛通- 最 高1.77
- 今 开1.67
- 成交量 1.95万股
- 最 低 1.6201
- 昨 收 1.64
- 总市值 7372.55万
- 52周最高 3.798
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 1.51
- 委 比 -13.81%
- 总股本 4237.10万
- 历史最高 27890625.00
- 量 比 1.10
- 振 幅 9.14%
- 历史最低 0.806
- 每 手 1
- 风险率 0.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD, Inc. announced that its Compensation Committee approved inducement grants of 36,118 restricted shares to one new non-executive employee, outside its 2021 Equity Incentive Plan, under the 2024 Inducement Plan. The shares vest over three years, with one-third vesting annually. The grants comply with Nasdaq Listing Rule 5635(c)(4).
01-20 14:00
InspireMD Publishes Data From Its C-GUARDIANS Pivotal Study Journal Of The American College of Cardiology
InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company's C-GUARDIANS pivotal
01-12 22:03
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)
The C-GUARDIANS pivotal trial results, published in the Journal of the American College of Cardiology, demonstrated the CGuard® Prime Carotid Stent System's safety and efficacy in treating carotid artery stenosis. The study achieved historically low rates of disabling stroke or myocardial infarction (0.95% at 30 days) and ipsilateral stroke (1.93% at one year) among high-risk patients, including those with symptomatic disease. The trial enrolled ...
01-12 14:00
InspireMD’s New Study on Neuroprotection System: A Potential Game-Changer?
InspireMD Inc ($NSPR) announced an update on their ongoing clinical study. Insp...
2025-12-15 00:40
Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting
InspireMD highlights CREST-2 trial results showing carotid artery stenting combined with medical therapy reduces stroke risk in asymptomatic carotid stenosis patients compared to intensive medical therapy alone. The study, published in the New England Journal of Medicine, also found carotid endarterectomy did not provide significant benefits over medical management in this patient population.
2025-11-24 12:30
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>MIAMI, Nov. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. announced that its Compensation Committee approved inducement grants of 122,054 restricted shares to 8 new non-executive employees under its 2024 Inducement Plan, effective November 20, 2025. The restricted stock vests over three years, with one-third vesting annually. This move aligns with Nasdaq Listing Rule 5635(c)(4). InspireMD, which focuses on developing carotid stents using its Mi...
2025-11-21 14:00
InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference
InspireMD, Inc. announced its participation in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference on December 3rd at 12:30 pm ET. The event will be available via live audio webcast and replay on the company’s website. InspireMD aims to make its carotid stenting products the industry standard using its proprietary MicroNet mesh technology.
2025-11-19 21:42
InspireMD Reports Record Q3 Revenue with U.S. Launch
InspireMD ( ($NSPR) ) has provided an update. On November 4, 2025, InspireMD re...
2025-11-05 05:53
InspireMD GAAP EPS of -$0.17
InspireMD press release (NSPR): Q3 GAAP EPS of -$0.17. As of September 30, 2025, cash and cash equivalents and marketable securities were $63.4 million compared to $34.6 million as of December 31, 202...
2025-11-04 20:29
InspireMD Reports Third Quarter 2025 Financial Results
Miami, Nov. 4, 2025 – InspireMD, Inc. reported strong Q3 2025 results with a 39% revenue increase to $2.5 million, driven by the successful U.S. launch of its CGuard Prime carotid stent system. Despite a 57% rise in operating expenses to $13.9 million and a net loss of $12.7 million, the company’s cash reserves grew to $63.4 million following a $58 million equity raise. Key highlights include over 100 U.S. procedures, leadership team expansions, ...
2025-11-04 12:00
